New Drug Application for a Single Pack Containing TAKECAB for Eradication of Helicobacter pylori in Japan
TAKECAB was launched in Japan on February 26 this year. The eradication of H. pylori for “Gastric ulcer, duodenal ulcer, gastric mucosa-associated lymphatic tissue (MALT) lymphoma, idiopathic thrombocytopenic purpura, gastric diseases after endoscopic resection of early stage gastric cancer, and H. pylori gastritis” are approved as well.
Each blister card has the daily dose of the single pack containing two antibacterial drugs and TAKECAB for the treatment of H. pylori eradication. The packaging helps improve the medication adherence of patients. By ensuring that patients follow the dosage and administration of each drug used for the treatment of H. pylori eradication, the effectiveness of the treatment is expected to improve further. In addition, we consider that this will also increase the convenience of healthcare professionals, helping us contribute further to the treatment of eradication in Japan.
Takeda Pharmaceutical Company Limited
Located in Osaka, Japan, Takeda is a global research-based company focusing mainly on pharmaceuticals. As the largest pharmaceutical company in Japan and a global leader in the industry, Takeda is committed to improving the health of people worldwide as a leading innovator in medicine.
Otsuka Pharmaceutical Company, Limited
Otsuka is a global healthcare company with the corporate philosophy: “Otsuka – people creating new products for better health worldwide.” Otsuka researches, develops, manufactures, and markets innovative and original products, focusing on pharmaceutical products for treating diseases and nutraceutical products to maintain everyday health.
Комментарии